Cytori Therapeutics Demonstrates Human Adipose-Derived Adult Stem Cells Have the Potential to Differentiate into Spinal Disc.SAN DIEGO -- Cytori Therapeutics, Inc. (Frankfurt: XMP (X/Open Management Protocol) A high-level network management protocol governed by X/Open. Network management software written to the XMP interface is shielded from the details of the underlying SNMP or CMIP protocols. ), today announced research results illustrating that human adipose-derived adult stem cells can differentiate into cells displaying the phenotype of nucleus pulposus Nucleus pulposus (NP) The center portion of the intervertebral disk that is made up of a gelatinous substance. Mentioned in: Chemonucleolysis, Herniated Disk (NP) cells. The nucleus pulposus, which forms the soft gel-like center of an intervertebral intervertebral /in·ter·ver·te·bral/ (-ver´te-bral) situated between two contiguous vertebrae; see under disk. in·ter·ver·te·bral adj. Located between vertebrae. disc, is adversely affected in degenerative disc disease Degeneration of the intervertebral disc, which is often called "degenerative disc disease" (DDD) of the spine, is a common disorder of the lower spine and for some people can cause low back pain and/or leg pain (sciatica). . These data were presented (Abstract #: P116) at the 20th annual North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Spine Society conference September 27 - October 1, 2005 in Philadelphia, Pennsylvania. "Our research demonstrates the potential for using human adipose-derived stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young in treating patients with degenerative disc disease," stated Christopher J. Calhoun, Chief Executive Officer for Cytori Therapeutics. "We are encouraged by these early findings and have initiated preclinical animal studies to further evaluate the effect of these cells, in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. , on injured discs." In a poster presentation at the Conference, scientists from the Skeletal Tissue Engineering Group Amsterdam (STEGA) and Cytori Therapeutics demonstrated that an NP-phenotype was observed when adipose adipose /ad·i·pose/ (ad´i-pos) 1. fatty. 2. the fat present in the cells of adipose tissue. ad·i·pose adj. Of, relating to, or composed of animal fat; fatty. stem cells were grown in conditions that can be adapted to clinical practice. The human adipose stem cells and NP cells were co-cultured for 14 days. RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic expression analysis found the presence of genes which are markers of mature NP cells. One of the genes in particular forms a protein that is critical to the function of the nucleus pulposus. About Cytori Therapeutics Cytori Therapeutics (Frankfurt: XMP) is discovering and developing proprietary cell-based therapeutics utilizing adult stem cells derived from adipose, also known as fat tissue. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution(TM) system to isolate and concentrate a patient's own stem cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics' future operating results and financial position. Such statements are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially. Some of these risks and uncertainties are described (under the heading "Risk Factors") in Cytori Therapeutics' 2004 Form 10-K annual report for the year ended December 31, 2004 and subsequent SEC filings, which are available through the Company's web site. Cytori Therapeutics assumes no responsibility to update any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion